AstraZeneca Reports the Results of Tagrisso (osimertinib) in P-III ADAURA Study for the Adjuvant Treatment of Patients Early-Stage EGFR-Mutated Lung Cancer

 AstraZeneca Reports the Results of Tagrisso (osimertinib) in P-III ADAURA Study for the Adjuvant Treatment of Patients Early-Stage EGFR-Mutated Lung Cancer

AstraZeneca Reports the Results of Tagrisso (osimertinib) in P-III ADAURA Study for the Adjuvant Treatment of Patients Early-Stage EGFR-Mutated Lung Cancer

Shots:

  • The P-III ADAURA study involves assessing of Tagrisso (80mg, qd, PO) vs PBO for the adjuvant treatment of 682 patients with stage IB, II, IIIA EGFRm NSCLC following complete tumor resection and adjuvant CT as indicated for 3yrs. or until disease recurrence
  • Results: 82% reduction in the risk of CNS recurrence or death; patients having recurrence events or deaths (11% vs 46%); patients having metastatic recurrence (38% vs 61%). In a posthoc analysis, disease recurrence in the brain @18mos. 83% reduction in risk of disease recurrence or death, presented at ESMO 2020
  • Tagrisso is an irreversible EGFR-TKI with clinical activity against CNS metastases and has received BT designation in Jul’2020 for the adjuvant treatment of patients with early-stage EGFRm NSCLC after complete tumor resection with curative intent

Click here ­to­ read full press release/ article | Ref: AstraZeneca | Image: IndiaMart

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post